CoChat
Sign Up
Cited by 1,093Diabetes and associated disordersT-cell and B-cell ImmunologyDiabetes Management and Research

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Open access
Pescovitz, Mark D., Greenbaum, Carla J., Krause-Steinrauf, Heidi, Becker, Dorothy J., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Marks, Jennifer B., McGee, Paula F., Moran, Antoinette M., Raskin, Philip, Rodriguez, Henry, Schatz, Desmond A., Wherrett, Diane, Wilson, Darrell M., Lachin, John M., Skyler, Jay S.·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0904452PMC PMC6410357
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte-mediated diseases. It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes. METHODS: We conducted a randomized, double-blind study in which 87 patients between 8 and 40 years of age who had newly diagnosed type 1 diabetes were assigned to receive infusions of rituximab or placebo on days 1, 8, 15, and 22 of the study. The primary outcome, assessed 1 year after the first infusion, was the geometric mean area under the curve (AUC) for the serum C-peptide level during the first 2 hours of a mixed-meal tolerance test. Secondary outcomes included safety and changes in the glycated hemoglobin level and insulin dose. RESULTS: At 1 year, the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group. The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin. Between 3 months and 12 months, the rate of decline in C-peptide levels in the rituximab group was significantly less than that in the placebo group. CD19+ B lymphocytes were depleted in patients in the rituximab group, but levels increased to 69% of baseline values at 12 months. More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion. The reactions appeared to be minimal with subsequent infusions. There was no increase in infections or neutropenia with rituximab. CONCLUSIONS: A four-dose course of rituximab partially preserved beta-cell function over a period of 1 year in patients with type 1 diabetes. The finding that B lymphocytes contribute to the pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of patients with this condition. (ClinicalTrials.gov number, NCT00279305.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0904452

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 39 references

Research works printed but not linked: 1

  1. Lapointe R, 2003, Cancer Res, 63, 2836

Cited by

Sorted by citations

Items 601–700 of 1,000

Related

See all

Metadata

Authors
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., Raskin, P., Rodriguez, H., Schatz, D. A., Wherrett, D., Wilson, D. M., Lachin, J. M., & Skyler, J. S.
Affiliations
  • Indiana University School of Medicine (US)
  • Benaroya Research Institute (US)
  • George Washington University (US)
  • University of Pittsburgh (US)
  • University of California, San Francisco (US)
  • Columbia University (US)
  • University of Colorado Health (US)
  • University of Miami (US)
  • University of Minnesota (US)
  • The University of Texas Southwestern Medical Center (US)
  • University of Florida (US)
  • University of Toronto (CA)
  • Stanford University (US)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2009-11-26
Volume
361
Issue
22
Pages
2143-2152
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa0904452
PMC
PMC6410357
OpenAlex
W2064431167
Cited by
1,093
References
39
Citations by year
2026: 45 · 2025: 65 · 2024: 56 · 2023: 55 · 2022: 56 · 2021: 64 · 2020: 53 · 2019: 49 · 2018: 49 · 2017: 45 · 2016: 57 · 2015: 63 · 2014: 72 · 2013: 98 · 2012: 89
FWCI
51.38
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • Purdue University Indianapolis (Indiana University) (submittedVersion)
  • PMC
Funders
  • American Diabetes Association
  • Juvenile Diabetes Research Foundation International
  • Eli Lilly and Company
  • Biogen
  • Osiris Therapeutics
  • MacroGenics
  • National Institutes of Health
  • Genentech
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases (R21DK077329, U01DK061058, U01DK061034, U01DK103282)
  • National Institute of Child Health and Human Development
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
rituximab, B-cell depletion, type 1 diabetes, beta-cell preservation, anti-CD20 monoclonal antibody, C-peptide, CD19+ B cells, immunopathogenesis, newly diagnosed type 1 diabetes, HbA1c, insulin dose
MeSH terms
Rituximab, Adolescent, Adult, Antibodies, Monoclonal, B-Lymphocytes, C-Peptide, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Immunoglobulin M, Immunologic Factors, Male, Area Under Curve, Insulin-Secreting Cells, Young Adult, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review